How do you approach selecting biologic therapy vs non-biologic DMARD (such as methotrexate) as initial therapy in patients with new RA diagnosis with significant erosive disease?  

This question is part of a collaboration with RheumMadness and is specifically in reference to: NORD-STAR (Østergaard et al., PMID 37423647).



Answer from: at Community Practice
Comments
at Sheridan Memorial Hospital
Very good points Dr. @Paul J. DeMarco, all care sh...
Sign in or Register to read more

Answer from: at Academic Institution

Answer from: at Community Practice
Comments
at Arthritis Associates
The problem I face is that insurance companies and...
Sign in or Register to read more

Answer from: at Community Practice

Answer from: at Academic Institution